Skip to main content
Top
Gepubliceerd in: Quality of Life Research 9/2019

29-04-2019

Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients

Auteurs: Leung Li, Stephen L. Chan, Frankie Mo, Edwin P. Hui, Jane Koh, Allen KC Chan, Nelson LS Tang, Cheuk M. Chu, Joyce Hui, Kit F. Lee, Simon Yu, Winnie Yeo

Gepubliceerd in: Quality of Life Research | Uitgave 9/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Both Inflammation and health-related quality of life (HRQoL) are independent prognosticators in HCC patients. We hypothesized that inflammation can cause impairment in HRQoL and investigated the correlation between inflammatory status and HRQoL in HCC patients.

Methods

Clinical, laboratory and HRQoL (using EORTC QLQ-C30, QLQ-HCC18, C30 and HCC18 index-scores) data were prospectively collected from HCC patients at diagnosis. Correlation analyses were performed between HRQoL and inflammation-based markers including C-reactive protein (CRP), CRP/albumin ratio (CRP/alb), Glasgow Prognostic Score (GPS), Inflammation-Based Index (IBI) and Prognostic Index (PI).

Results

Among 445 HCC patients, higher inflammatory states were significantly correlated with worse HRQoL. For CRP and CRP/alb ratio, the HRQoL factors with higher correlations included C30 and HCC18 index-scores, certain QLQ-C30 domains and items (‘physical functioning’, ‘role functioning’, ‘fatigue’, ‘pain’, ‘appetite loss’) and QLQ-HCC18 items (‘fatigue’, ‘body image’, ‘nutrition’ and ‘abdominal swelling’), where the Pearson’s correlation coefficients were up to 0.416. Multivariate analyses indicated that worse HRQoL factors were significantly correlated with worse scores in GPS, IBI and PI.

Conclusion

In HCC patients, inflammatory status correlates with HRQoL at presentation. In particular, relatively stronger correlations with CRP-based markers have been observed in HRQoL scales that assess constitutional symptoms (QLQ-C30 ‘physical functioning’, ‘role functioning’, ‘fatigue’, ‘appetite loss’ and QLQ-HCC18 ‘fatigue’ and ‘nutrition’) and tumor burden (QLQ-C30 ‘pain’ and QLQ-HCC18 ‘abdominal swelling’ and ‘body image’). Future studies are warranted to evaluate whether intervention that reduces inflammation could improve HRQoL in HCC patients.
Literatuur
2.
go back to reference Kim, U. B., Doo, C. J., Baek, S. H., Kim, J. H., Lee, H. B., Park, S. K., et al. (1989). Natural history and prognostic factors of primary hepatocellular carcinoma: Study of 70 untreated patients. Korean Journal of Internal Medicine, 4(2), 136–141.CrossRefPubMed Kim, U. B., Doo, C. J., Baek, S. H., Kim, J. H., Lee, H. B., Park, S. K., et al. (1989). Natural history and prognostic factors of primary hepatocellular carcinoma: Study of 70 untreated patients. Korean Journal of Internal Medicine, 4(2), 136–141.CrossRefPubMed
4.
go back to reference Pawarode, A., Voravud, N., Sriuranpong, V., Kullavanijaya, P., & Patt, Y. Z. (1998). Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients. American Journal of Clinical Oncology, 21(4), 386–391.CrossRefPubMed Pawarode, A., Voravud, N., Sriuranpong, V., Kullavanijaya, P., & Patt, Y. Z. (1998). Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients. American Journal of Clinical Oncology, 21(4), 386–391.CrossRefPubMed
5.
go back to reference Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., et al. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56(4), 918–928.CrossRefPubMed Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., et al. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56(4), 918–928.CrossRefPubMed
7.
go back to reference Yeo, W., Mo, F. K., Koh, J., Chan, A. T., Leung, T., Hui, P., et al. (2006). Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Annals of Oncology, 17(7), 1083–1089.CrossRefPubMed Yeo, W., Mo, F. K., Koh, J., Chan, A. T., Leung, T., Hui, P., et al. (2006). Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Annals of Oncology, 17(7), 1083–1089.CrossRefPubMed
8.
go back to reference Bonnetain, F., Paoletti, X., Collette, S., Doffoel, M., Bouche, O., Raoul, J. L., et al. (2008). Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: Results from two French clinical trials. Quality of Life Research, 17(6), 831–843. https://doi.org/10.1007/s11136-008-9365-y.CrossRefPubMed Bonnetain, F., Paoletti, X., Collette, S., Doffoel, M., Bouche, O., Raoul, J. L., et al. (2008). Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: Results from two French clinical trials. Quality of Life Research, 17(6), 831–843. https://​doi.​org/​10.​1007/​s11136-008-9365-y.CrossRefPubMed
9.
go back to reference Diouf, M., Filleron, T., Barbare, J. C., Fin, L., Picard, C., Bouche, O., et al. (2013). The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. Journal of Hepatology, 58(3), 509–521.CrossRefPubMed Diouf, M., Filleron, T., Barbare, J. C., Fin, L., Picard, C., Bouche, O., et al. (2013). The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. Journal of Hepatology, 58(3), 509–521.CrossRefPubMed
15.
22.
go back to reference Yamamura, K., Sugimoto, H., Kanda, M., Yamada, S., Nomoto, S., Nakayama, G., et al. (2014). Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepatobiliary Pancreatic Sciences, 21(9), 682–688. https://doi.org/10.1002/jhbp.114.CrossRefPubMed Yamamura, K., Sugimoto, H., Kanda, M., Yamada, S., Nomoto, S., Nakayama, G., et al. (2014). Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepatobiliary Pancreatic Sciences, 21(9), 682–688. https://​doi.​org/​10.​1002/​jhbp.​114.CrossRefPubMed
23.
go back to reference Pinato, D. J., Karamanakos, G., Arizumi, T., Adjogatse, D., Kim, Y. W., Stebbing, J., et al. (2014). Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: A prospective study. Alimentary Pharmacology & Therapeutics, 40(11–12), 1270–1281. https://doi.org/10.1111/apt.12992.CrossRef Pinato, D. J., Karamanakos, G., Arizumi, T., Adjogatse, D., Kim, Y. W., Stebbing, J., et al. (2014). Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: A prospective study. Alimentary Pharmacology & Therapeutics, 40(11–12), 1270–1281. https://​doi.​org/​10.​1111/​apt.​12992.CrossRef
26.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed
27.
go back to reference Blazeby, J. M., Currie, E., Zee, B. C., Chie, W. C., Poon, R. T., & Garden, O. J. (2004). Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. European Journal of Cancer, 40(16), 2439–2444.CrossRefPubMed Blazeby, J. M., Currie, E., Zee, B. C., Chie, W. C., Poon, R. T., & Garden, O. J. (2004). Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. European Journal of Cancer, 40(16), 2439–2444.CrossRefPubMed
34.
go back to reference Huang, C. C., Lien, H. H., Sung, Y. C., Liu, H. T., & Chie, W. C. (2007). Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22. Psychooncology, 16(10), 945–949. https://doi.org/10.1002/pon.1158.CrossRefPubMed Huang, C. C., Lien, H. H., Sung, Y. C., Liu, H. T., & Chie, W. C. (2007). Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22. Psychooncology, 16(10), 945–949. https://​doi.​org/​10.​1002/​pon.​1158.CrossRefPubMed
36.
go back to reference Zhao, H., & Kanda, K. (2000). Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Quality of Life Research, 9(2), 129–137.CrossRefPubMed Zhao, H., & Kanda, K. (2000). Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Quality of Life Research, 9(2), 129–137.CrossRefPubMed
37.
go back to reference Cheng, J. X., Liu, B. L., Zhang, X., Zhang, Y. Q., Lin, W., Wang, R., et al. (2011). The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Medical Research Methodology, 11, 56. https://doi.org/10.1186/1471-2288-11-56.CrossRefPubMedPubMedCentral Cheng, J. X., Liu, B. L., Zhang, X., Zhang, Y. Q., Lin, W., Wang, R., et al. (2011). The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Medical Research Methodology, 11, 56. https://​doi.​org/​10.​1186/​1471-2288-11-56.CrossRefPubMedPubMedCentral
39.
go back to reference Chie, W. C., Hong, R. L., Lai, C. C., Ting, L. L., & Hsu, M. M. (2003). Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Quality of Life Research, 12(1), 93–98.CrossRefPubMed Chie, W. C., Hong, R. L., Lai, C. C., Ting, L. L., & Hsu, M. M. (2003). Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Quality of Life Research, 12(1), 93–98.CrossRefPubMed
41.
go back to reference Chie, W. C., Blazeby, J. M., Hsiao, C. F., Chiu, H. C., Poon, R. T., Mikoshiba, N., et al. (2012). International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology, 55(4), 1122–1129. https://doi.org/10.1002/hep.24798.CrossRefPubMed Chie, W. C., Blazeby, J. M., Hsiao, C. F., Chiu, H. C., Poon, R. T., Mikoshiba, N., et al. (2012). International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology, 55(4), 1122–1129. https://​doi.​org/​10.​1002/​hep.​24798.CrossRefPubMed
42.
go back to reference Lachin, J. M. (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials, 2(2), 93–113.CrossRefPubMed Lachin, J. M. (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials, 2(2), 93–113.CrossRefPubMed
44.
go back to reference Panahi, Y., Saadat, A., Beiraghdar, F., & Sahebkar, A. (2014). Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res., 28(10), 1461–1467. https://doi.org/10.1002/ptr.5149.CrossRefPubMed Panahi, Y., Saadat, A., Beiraghdar, F., & Sahebkar, A. (2014). Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res., 28(10), 1461–1467. https://​doi.​org/​10.​1002/​ptr.​5149.CrossRefPubMed
Metagegevens
Titel
Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients
Auteurs
Leung Li
Stephen L. Chan
Frankie Mo
Edwin P. Hui
Jane Koh
Allen KC Chan
Nelson LS Tang
Cheuk M. Chu
Joyce Hui
Kit F. Lee
Simon Yu
Winnie Yeo
Publicatiedatum
29-04-2019
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02190-0

Andere artikelen Uitgave 9/2019

Quality of Life Research 9/2019 Naar de uitgave